Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.9%
0%
-10.9%
6 Months
-2.93%
0%
-2.93%
1 Year
32.7%
0%
32.7%
2 Years
64.1%
0%
64.1%
3 Years
15.43%
0%
15.43%
4 Years
70.72%
0%
70.72%
5 Years
48.95%
0%
48.95%
Orion Oyj for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.23%
EBIT Growth (5y)
5.61%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
1.24
Tax Ratio
20.16%
Dividend Payout Ratio
69.83%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
40.73%
ROE (avg)
29.77%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
7.94
EV to EBIT
15.92
EV to EBITDA
13.23
EV to Capital Employed
7.06
EV to Sales
4.43
PEG Ratio
0.24
Dividend Yield
NA
ROCE (Latest)
44.33%
ROE (Latest)
41.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
416.80
355.20
17.34%
Operating Profit (PBDIT) excl Other Income
116.90
90.80
28.74%
Interest
1.20
1.00
20.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
82.50
61.30
34.58%
Operating Profit Margin (Excl OI)
246.90%
217.10%
2.98%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 17.34% vs -18.23% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 34.58% vs -16.49% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,541.40
1,191.30
29.39%
Operating Profit (PBDIT) excl Other Income
498.70
284.60
75.23%
Interest
8.40
5.70
47.37%
Exceptional Items
-38.00
29.70
-227.95%
Consolidate Net Profit
329.90
216.80
52.17%
Operating Profit Margin (Excl OI)
290.20%
196.40%
9.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 29.39% vs -10.65% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 52.17% vs -37.97% in Dec 2023
About Orion Oyj 
Orion Oyj
Pharmaceuticals & Biotechnology
Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
Company Coordinates 
Company Details
Orionintie 1A , ESPOO None : 02200
Registrar Details






